Clinical and Biorepository Core
Clinical and Biorepository Core
批准号:
10404141
负责人:
Robyn Therese Domsic
金额:
$27.03万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-20 至 2027-08-31
关键词:
AddressAgeAutoantibodiesAutoimmune DiseasesBiologicalBiometryBloodBlood VesselsCause of DeathCell modelCellsClinicalClinical DataCollaborationsCollectionDataDevelopmentDiffuse SclerodermaDisciplineDiseaseDisease modelEnsureEvaluationFacultyFamiliarityGenerationsGoalsGoldHumanIndividualInstitutionInterdisciplinary StudyInterstitial Lung DiseasesLinkLungLung TransplantationModelingMolecularMorbidity - disease rateNatureOrganOrgan ProcurementsPathogenesisPathway interactionsPatientsProtocols documentationPublic Health SchoolsPublicationsRecording of previous eventsResearchResearch PersonnelResearch Project GrantsResourcesRheumatologySchoolsSclerodermaSerumSkinSkin TissueSliceSpecimenStandardizationStatistical Data InterpretationStatistical ModelsStructure of parenchyma of lungStudy modelsSystemic SclerodermaTechniquesTestingTherapeuticTherapeutic InterventionTissue ModelTissue SampleTissuesTranslational ResearchTransplantationUniversitiesbasebiobankclinical data repositoryclinical investigationclinical phenotypecohortdata repositorydesigndisabilityexperienceexperimental studyhuman diseaseimprovedmortalitymultidisciplinaryprogramsprospectivepulmonary arterial hypertensionrepositorysingle cell analysisskin disordertissue processingtranslational research programtranslational study
中文摘要
摘要
系统性硬化症(SSC)是最致命的自身免疫性疾病。与SSC相关的主要原因
死亡率是间质性肺病(ILD)和肺动脉高压(PAH)的并发症,
皮肤病是发病率的一个重要因素。利用现有的优势和优势
匹兹堡大学内的多个部门和学院,核心B是提供资源的关键,
专业知识和支持,以帮助研究SSC和ITS的协同研究项目的总体计划目标
在拟议的翻译研究计划中,ILD、PAH和皮肤增厚的重要并发症。在……里面
为了实现这一目标,核心B有以下四个具体目标:目标1:提供临床数据存储库
对SSc患者进行纵向随访,以陪同血液和皮肤生物标本支持项目
#1、#2和#3。这将使用匹兹堡大学长期和公认的SSC观察性队列
临床和配型血清库。这一长达40年的观察队列将促进两者之间的联系
用于机制研究和统计建模的生物显微镜的横断面和纵向临床数据。目标
2:为了丰富我们目前的肺和皮肤组织、细胞、精密切片和从以下来源获得的血清的存储库
在项目#1、#2和#3中应用的正常个人和患有SSC的个人。
弥漫性SSC患者,移植自SSC患者的肺组织及皮肤和肺
健康对照/捐献者将接受最先进的分子生物学分析,特别是单细胞分析,
组织病理学特征,以及细胞和组织模型的生成,将用于支持这三个
科学项目。目标3:协助项目#1、#2和#3的项目调查人员设计和
使用生物库中的生物标本和模型进行实验。核心B将提供
在开发和标准化基于细胞和组织的EX的新协议和技术方面的专业知识
活体模型,实施适当的设置,以确保成功评估机械路径和
对SSc进行治疗干预,并进行针对SSc的金标准自身抗体检测
包括在统计分析中。目标4:向项目1、2和3中的调查人员提供统计数据
成功完成临床数据分析和链接所需的支持。
英文摘要
ABSTRACT
Systemic sclerosis (SSc) is the most lethal of the autoimmune diseases. The primary causes of SSc-related
mortality are the complications of interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), with
skin disease being a significant contributor to morbidity. Using the complimentary and existing strengths of
multiple divisions and Schools within the University of Pittsburgh, Core B is crucial to providing the resources,
expertise and support to help the overall program goal of synergistic research projects studying SSc and its
important complications of ILD, PAH and skin thickening in the proposed translational research program. In
order to accomplish this, Core B has the following four Specific Aims: Aim 1: To provide a clinical data repository
of longitudinally-followed SSc patients to accompany the blood and skin biologic specimens to support Projects
#1, #2, and #3. This will use the longstanding and recognized University of Pittsburgh observational SSc cohort
clinical and matching serum databank. This 40-year observational cohort will facilitate the linking of both cross-
sectional and longitudinal clinical data with biospecimens for mechanistic studies and statistical modeling. Aim
2: To enrich our current repository of lung and skin tissue, cells, precision cut slices, and serum procured from
normal individuals and individuals with SSc for application in Projects #1, #2, and #3. In this Aim skin from
patients with diffuse SSc, explanted lung tissue from SSc patients undergoing lung transplant and skin and lung
healthy controls/donors will undergo state-of the art molecular biological analysis, especially single cell analysis,
histopathological characterization, and cell and tissue model generation which will be used to support all three
scientific projects. Aim 3: To assist program investigators from Projects #1, #2, and #3 in the design and
implementation of experiments using biological specimens and models from the Biobank. Core B will provide
expertise in the development and standardization of new protocols and technique for cell and tissue-based ex
vivo models, implement proper setups to ensure the successful evaluation of mechanistic pathways and
therapeutic interventions for SSc, and perform gold standard SSc-specific serum autoantibody testing to be
included in statistical analysis. Aim 4: To provide the investigators in Projects #1, #2 and #3 with the statistical
support required to successfully complete the analyses and linking of clinical data.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical and Biorepository Core
-
批准号:10705626
-
项目类别:
-
资助金额:$27.03万
-
财政年份:2022
-
负责人:Robyn Therese Domsic
-
依托单位:
Addressing Critical Knowledge Gaps in Early Diffuse Scleroderma Trial Design
-
批准号:9685112
-
项目类别:
-
资助金额:$20.66万
-
财政年份:2017
-
负责人:Robyn Therese Domsic
-
依托单位:
Effect of Atorvastatin on Endothelial Function and Raynaud in Diffuse Scleroderma
-
批准号:8832216
-
项目类别:
-
资助金额:$20.16万
-
财政年份:2015
-
负责人:Robyn Therese Domsic
-
依托单位:
Effect of Atorvastatin on Endothelial Function and Raynaud in Diffuse Scleroderma
-
批准号:9000622
-
项目类别:
-
资助金额:$16.87万
-
财政年份:2015
-
负责人:Robyn Therese Domsic
-
依托单位:
Core 1: Clinical and Biological Specimen Core
-
批准号:10022102
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2011
-
负责人:Robyn Therese Domsic
-
依托单位:
Core 1: Clinical and Biological Specimen Core
-
批准号:10262932
-
项目类别:
-
资助金额:$22.71万
-
财政年份:2011
-
负责人:Robyn Therese Domsic
-
依托单位:
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma
-
批准号:7921437
-
项目类别:
-
资助金额:$12.05万
-
财政年份:2009
-
负责人:Robyn Therese Domsic
-
依托单位:
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma
-
批准号:8209055
-
项目类别:
-
资助金额:$12.33万
-
财政年份:2009
-
负责人:Robyn Therese Domsic
-
依托单位:
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma
-
批准号:8600242
-
项目类别:
-
资助金额:$12.49万
-
财政年份:2009
-
负责人:Robyn Therese Domsic
-
依托单位:
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma
-
批准号:8451527
-
项目类别:
-
资助金额:$12.49万
-
财政年份:2009
-
负责人:Robyn Therese Domsic
-
依托单位:
Developing Clinical Risk Predictions Rules in Early Diffuse Schleroderma
-
批准号:7714129
-
项目类别:
-
资助金额:$11.78万
-
财政年份:2009
-
负责人:Robyn Therese Domsic
-
依托单位:
Core 1: Clinical and Biological Specimen Core
-
批准号:9370323
-
项目类别:
-
资助金额:$18.7万
-
财政年份:--
-
负责人:Robyn Therese Domsic
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: